Health Canada has approved Lundbeck’s VYEPTI migraine preventative treatment for adults who experience a migraine episode at least four days per month.
It thus becomes the first intravenous treatment of its kind authorized in the country.
Its unique 30-minute infusion process allows users to feel the effects the day after administration and maintain them for up to three months. Preventive treatment is therefore received four times a year.
“Our therapeutic arsenal has been enriched with an intravenous option which is associated with response rates of 50% and 75% and which is well tolerated,” says Dr.re Elizabeth Leroux, neurologist and president of Migraine Canada and the Canadian Headache Society. This means that rapid and lasting relief could be within the reach of many people who are often struggling with a migraine episode. ”
Note that VYEPTI will also be accompanied by a patient support program that will facilitate and support the administration of this treatment. (N.P./IJL)